Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ganoderma lucidum spore powder + doxorubicin + cisplatin
- Development stage
- Unknown
- Lead developer
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This therapeutic regimen is a combination therapy being evaluated for the treatment of osteosarcoma following surgical resection. It consists of **Ganoderma lucidum spore powder**, a natural botanical product, administered alongside conventional chemotherapy agents **doxorubicin** and **cisplatin**. Ganoderma lucidum spore powder contains active triterpenoids and polysaccharides that are thought to regulate the tumor immune microenvironment and inhibit growth and metastasis. Doxorubicin is an anthracycline that works by intercalating DNA and inhibiting topoisomerase II, while cisplatin is a platinum-based agent that forms DNA cross-links, leading to apoptosis in rapidly dividing cancer cells. The combination is currently being studied in a Phase II clinical trial sponsored by the Second Affiliated Hospital, School of Medicine, Zhejiang University, to improve the 5-year survival rate and prognosis of osteosarcoma patients.
- Other names
- Ganoderma lucidum spore powder + chemotherapyGanoderma lucidum spore powder + doxorubicin + cisplatin chemotherapy
02
Targets
TOP2A (DNA topoisomerase II)DNA
Beyond the preview
Go deeper on Ganoderma lucidum spore powder + doxorubicin + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ganoderma lucidum spore powder + doxorubicin + cisplatin.